"TCR CDR3 chemical complementarity to HPV epitopes is associated with a" by Deo Rei L Agnila, Rahul Jain et al.
 

USF-LVHN SELECT

TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer.

Publication/Presentation Date

4-11-2025

Abstract

Despite the fact that HPV vaccines are likely to lead to a significant reduction in cervical cancer occurrence, there remains cervical cancer incidence independent of the vaccine and cervical cancer arising in the absence of vaccination. Thus, continued efforts are needed to address the potential parameters of cervical cancer that could impact therapy and could lead to additional ways of reducing cervical cancer death rates. Adaptive immune receptor recombinations were obtained from the cancer genome atlas (TCGA) cervical cancer database through tumor exome and RNAseq files as well as from the independent Cancer Genome Characterization Initiative (CGCI) cervical cancer dataset. T-cell receptor (TCR) complementarity determining region-3's (CDR3s) were then assessed, based on chemical complementarity to human papillomavirus (HPV) T-cell epitopes. Results indicated increased overall survival probabilities consistently across the three TCR datasets with TCR CDR3 chemical complementarity to the same HPV epitopes, specifically immune epitope database (IEDB) designations: IEDB-1625373, IEDB-174148, and IEDB-110943. Among other potential applications of these results, the results may indicate HPV epitopes that could be useful targets for immunotherapy.

ISSN

1432-1777

Disciplines

Medical Education | Medicine and Health Sciences

PubMedID

40216662

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article

Link to Full Text

Share

COinS